Amarin

AMRN · NASDAQ

$11.48−$0.05 (−0.43%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.53

Latest news

Press releaseAug 31, 8:15 AM ETGlobe Newswire
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Press releaseAug 28, 8:15 AM ETGlobe Newswire
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Press releaseAug 24, 8:15 AM ETGlobe Newswire
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Press releaseJul 29, 7:00 AM ETGlobe Newswire
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
Press releaseJul 15, 8:00 AM ETGlobe Newswire
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
Press releaseJun 30, 4:15 PM ETGlobe Newswire
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Press releaseMay 27, 8:00 AM ETGlobe Newswire
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
NewsApr 29, 7:11 AM ET
Earnings Scheduled For April 29, 2026
Press releaseApr 29, 7:00 AM ETGlobe Newswire
Amarin Reports 2026 First Quarter Financial Results
Press releaseApr 15, 8:00 AM ETGlobe Newswire
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
Press releaseApr 8, 8:00 AM ETGlobe Newswire
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction
NewsFeb 25, 10:00 AM ET
Amarin Corp Q4 2025 Earnings Call Transcript
NewsFeb 25, 7:04 AM ET
Amarin Corp Earnings Report: Q4 Overview
NewsFeb 25, 7:03 AM ET
Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate
Press releaseFeb 25, 7:00 AM ETGlobe Newswire
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsOct 29, 7:17 AM ET
Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate
NewsOct 29, 7:11 AM ET
Earnings Scheduled For October 29, 2025
NewsOct 28, 5:01 PM ET
Earnings Outlook For Amarin Corp
NewsJun 24, 1:54 PM ETVandana Singh
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
NewsJun 24, 7:16 AM ET
Market-Moving News for June 24th
NewsMay 6, 10:02 AM ET
Exploring Amarin Corp's Earnings Expectations
NewsApr 11, 10:28 AM ETAvi Kapoor
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Press releaseMar 19, 12:45 PM ETBusiness Wire
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance
NewsNov 19, 7:52 AM ETAvi Kapoor
Top 3 Health Care Stocks You'll Regret Missing In Q4
Press releaseOct 30, 4:05 PM ETGlobe Newswire
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Earnings Scheduled For April 29, 2026

Amarin Reports 2026 First Quarter Financial Results

Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026

American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction

Amarin Corp Q4 2025 Earnings Call Transcript

Amarin Corp Earnings Report: Q4 Overview

Amarin Corp Q4 Adj. EPS $0.01 Beats $(0.56) Estimate, Sales $49.219M Miss $50.619M Estimate

Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Scheduled For February 25, 2026

Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate

Earnings Scheduled For October 29, 2025

Earnings Outlook For Amarin Corp

Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges

Market-Moving News for June 24th

Exploring Amarin Corp's Earnings Expectations

Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Top 3 Health Care Stocks You'll Regret Missing In Q4

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update